Shorter DAPT Tested Following CABG - Takeaways - MDSpire

Shorter DAPT Tested Following CABG

TOP-CABG compared 3 months vs 12 months of ticagrelor plus aspirin following bypass surgery.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 6 min

Share

  • 1

    Three months of ticagrelor-based dual antiplatelet therapy was noninferior to 12 months for saphenous vein graft occlusion after CABG.

  • 2

    The shorter DAPT duration significantly reduced clinically relevant bleeding compared to the longer duration in selected CABG patients.

  • 3

    The trial included 2,300 patients, with a mean age of 61.5 years, and assessed outcomes at 1 year post-surgery.

  • 4

    Major adverse cardiovascular events were similar between the 3-month and 12-month DAPT groups, but the trial was not powered for these differences.

  • 5

    Findings may not apply to all antiplatelet regimens or patients with specific conditions, limiting generalizability of the results.

Original Source(s)

Shorter DAPT Tested Following CABG

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Mavacamten Treatment Associated With Improved Diastolic Function, Remodeling Markers

Real-world follow-up data from 465 patients add to evidence from earlier randomized trials.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Can Sugammadex Lower Postsurgical Pulmonary Complications?

A large international randomized trial found fewer postoperative pulmonary complications with sugammadex vs. neostigmine following major abdominal or thoracic surgery, although the difference was driven primarily by reduced atelectasis.